MWNA
PHAT icon

Marshall Wace North America’s Phathom Pharmaceuticals PHAT Stock Holding History

Marshall Wace North America’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,436
Closed -$1.17M – 1643
2021
Q2 		$1.17M Sell
34,436
-3,094
-8% -$111K ﹤0.01% 965
2021
Q1 		$1.41M Sell
37,530
-31,466
-46% -$1.32M 0.01% 925
2020
Q4 		$2.29M Buy
+68,996
New +$2.8M 0.01% 721

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Marshall Wace North America's PHAT Position: Q3 2021 in Review

Marshall Wace North America sold out of Phathom Pharmaceuticals (PHAT) in Q3 2021, closing a stake of 34,436 shares — an estimated $1.17M sold.

Marshall Wace North America first reported a position in PHAT in Q4 2020 and held it in 3 quarters. The position peaked at $2.29M in Q4 2020. 84 funds tracked by Wall St. Rank hold PHAT as of Q3 2021.

  • Marshall Wace North America reported no remaining Phathom Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 34,436 Phathom Pharmaceuticals shares in Q3 2021, an estimated $1.17M.
  • Marshall Wace North America first reported a position in Phathom Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Marshall Wace North America's Phathom Pharmaceuticals position peaked at $2.29M in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.